Spheramine Titan/Schering

Grosset, D. and Grosset, K. (2005) Spheramine Titan/Schering. Current Opinion in Investigational Drugs, 6(7), pp. 722-728. (PMID:16044669)

Full text not currently available from Enlighten.


Spheramine, which is composed of microcarriers coated with dopamine-producing human retinal pigment epithelial cells, is being developed by Titan and Schering for the potential treatment of advanced Parkinson's disease. Phase II trials were ongoing in March 2005 and, at this time, were expected to be completed in the second half of 2006.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Grosset, Dr Donald and Grosset, Dr Katherine
Authors: Grosset, D., and Grosset, K.
College/School:College of Medical Veterinary and Life Sciences > Institute of Neuroscience and Psychology
College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
Journal Name:Current Opinion in Investigational Drugs
Publisher:Pharma Press Ltd
ISSN (Online):2040-3429

University Staff: Request a correction | Enlighten Editors: Update this record